Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 13/20 | 0.49 |
| ▸ | HTR2B | P41595 | 13/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4216952 | 0.92 | PDE4B (0.50) | HTR2CHTR2BPDE4B | |
| SCHEMBL15650817 | 0.91 | PDE4B (0.48) | HTR2CPDE4BHTR1ASLC6A2PRKCZ | |
| SCHEMBL5835805 | 0.81 | MAP2K1 (0.51) | HTR2CHTR2BHTR1ASLC6A2PRKCZ | |
| SCHEMBL5835326 | 0.81 | MAP2K1 (0.51) | HTR2CHTR2BHTR1ASLC6A2PRKCZ | |
| SCHEMBL4119970 | 0.80 | SLC6A2 (0.48) | HTR2CHTR2BPDE4BHTR1ASLC6A2 | |
| SCHEMBL8271827 | 0.80 | SLC6A2 (0.63) | HTR2CHTR2BPDE4BHTR1ASLC6A2 | |
| SCHEMBL8271831 | 0.80 | SLC6A2 (0.63) | HTR2CHTR2BPDE4BHTR1ASLC6A2 | |
| SCHEMBL9670802 | 0.80 | SLC6A2 (0.63) | HTR2CHTR2BPDE4BHTR1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL4133478 | 0.78 | SLC6A2 (0.61) | HTR2CHTR2BPDE4BHTR1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL4129951 | 0.78 | SLC6A2 (0.61) | HTR2CHTR2BPDE4BHTR1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263772-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20090093456-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093456-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | HTR2C 223/4885HTR2B 236/4885PDE4B 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.